Latest News

Boyd's next margin gains hinge on AI-driven shop productivity, a lever management expects to carry the remaining $35 million of savings through 2029.

The impressive growth in Intel's earnings could send the stock on a bull run over the coming year.

Customer prepayments now cover new capacity build-outs as 2027 guidance takes shape.

Nvidia stock declined immediately following the news.

Broadcom stock rebounded after a midterm-driven sell-off, aided by a low valuation, Anthropic's IPO, and NVIDIA turmoil, though state data center policies pose risks.

This fast-growing company has seen its stock cut in half. This is your wake-up call.

Three Dow giants pair market dominance with the financial strength to keep growing for the next decade.

Lilly's experimental GLP-1 is effective in treating osteoarthritic knee pain.

Moderna promised 20% sales growth in 2026 -- but Wall Street wants 24%.

Defense demand surged, but guidance was trimmed on longer sales cycles.

Energy royalties and a Côté buyback reshape the outlook.

Brookfield's latest results are a big reason I keep adding to my position.

John Ternus inherited a financial machine and is already spending on foldables, AI, and possibly servers.

Berkshire's concentrated stock portfolio seems to contradict his advice to buy the S&P 500.

ServiceNow (NYSE:NOW) is looking to employee productivity tools and artificial intelligence-powered back-office automation to drive growth, while facing increasing competition from smaller software companies, an executive said. Josh Kahn, senior vice president and general manager of Core Business W

CorMedix (NASDAQ:CRMD) reported lower third-quarter revenue as its DefenCath product entered a new reimbursement period, while management outlined plans to acquire substantially all of Heron Therapeutics’ assets and deferred 2027 guidance for the dialysis treatment. Revenue fell to $54.5 million fr

Fennec Pharmaceuticals (NASDAQ:FENC) reported third-quarter net product sales of $19.4 million, up 56% from a year earlier, as use of its hearing-protection drug PEDMARK expanded among new and existing customers. Chief Executive Officer Jeff Hackman said the company benefited from a larger sales or

Ascendis Pharma A/S (NASDAQ:ASND) reported third-quarter product revenue of EUR 366 million, up 89% from a year earlier, as sales of hypoparathyroidism treatment YORVIPATH and recently launched achondroplasia drug YUVIWEL grew. The company also raised its expectation for 2026 operating cash flow to

Cellebrite DI (NASDAQ:CLBT) reported third-quarter revenue and annual recurring revenue growth of 18% and 20%, respectively, as international sales and improving U.S. federal demand helped the digital forensics company exceed its guidance. The company reaffirmed its full-year annual recurring reven

Cardinal Infrastructure Group (NASDAQ:CDNL) withdrew its full-year 2026 revenue and adjusted EBITDA margin guidance after project estimate revisions and pricing pressure weighed on third-quarter profitability, even as revenue rose 65%. The company also postponed its proposed acquisition of Hughes B

Codere Online Luxembourg (NASDAQ:CDRO) reported third-quarter revenue growth of 31% and reiterated its full-year outlook, while warning that currency movements and new requirements in Spain could slow growth in the final months of 2026. Revenue rose to 62.6 million euros, while adjusted EBITDA incr

Aveanna Healthcare (NASDAQ:AVAH) raised its full-year 2026 outlook after reporting third-quarter revenue growth across all three of its businesses and a 25% increase in adjusted earnings. The home-based care provider expects full-year revenue above $2.695 billion and adjusted earnings before intere

AIR Global (NASDAQ:AIIR) reported higher third-quarter revenue and earnings as flavored shisha molasses shipments recovered from first-half supply chain disruption, though higher logistics and manufacturing costs weighed on margins. The company reiterated its 2026 operating outlook but raised its y

Boost Run (NASDAQ:BRUN) reported a sharp rise in third-quarter revenue as new GPU clusters came online, but project delays pushed a major deployment into 2027 and affected the company’s year-end recurring revenue outlook. Revenue rose to $39.9 million from $6.7 million a year earlier and $31.1 mill

Management details a hyperscaler prepayment and a capital-light growth model.